Get started
Author

Kuldeep S. Cheent

Observed names: Cheent, Kuldeep, K Cheent, K S Cheent, K. Cheent, Kuldeep Cheent, Kuldeep S Cheent
ORCID: 0009-0004-2206-5507
Observed ORCID: 0009-0004-2206-5507
OpenAlex ID: A5038009766
Case Report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's Disease
2010 · Kuldeep Cheent, Jonathan Nolan, et al. · Journal of Crohn s and Colitis · 411
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs
2021 · Heather J. Cordell, James J. Fryett, et al. · Journal of Hepatology · 194
Peptide antagonism as a mechanism for NK cell activation
2010 · Lena Fadda, Gwenoline Borhis, et al. · Proceedings of the National Academy of Sciences · 162
Natural killer cells: integrating diversity with function
2009 · Kuldeep Cheent, Salim I. Khakoo · Immunology · 126
Effects of Peptide on NK Cell-Mediated MHC I Recognition
2014 · Sorcha A. Cassidy, Kuldeep S. Cheent, et al. · Frontiers in Immunology · 70
PDF
Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial
2025 · Cynthia Levy, George F. Abouda, et al. · Journal of Hepatology · 37
PDF
Synergistic inhibition of natural killer cells by the nonsignaling molecule CD94
2013 · Kuldeep S. Cheent, Khaleel M. Jamil, et al. · Proceedings of the National Academy of Sciences · 35
PDF
STAT4-associated natural killer cell tolerance following liver transplantation
2016 · K M Jamil, T J Hydes, et al. · Gut · 31
PDF
Wireless capsule endoscopy in the investigation of intestinal Behcet's syndrome
2008 · S. S. Hamdulay, K. Cheent, et al. · Rheumatology · 29
Beta-blockers or Placebo for Primary Prophylaxis (BOPPP) of oesophageal varices: study protocol for a randomised controlled trial
2024 · Vishal C. Patel, Mark J. McPhail, et al. · Trials · 11
PDF
Recurrent Campylobacter jejuni Infection in an Immunodeficient Patient Treated with Repeated Faecal Microbiota Transplant (FMT)—A Case Report
2022 · Blair Merrick, Aravind Gokul Tamilarasan, et al. · Infectious Disease Reports · 9
PDF
OS-089 Elafibranor for primary sclerosing cholangitis: the ELMWOOD phase II randomised controlled trial
2025 · Cynthia Levy, George Abouda, et al. · Journal of Hepatology · 4
A case report of Adult-onset Still’s disease presenting with acute fibrinous and organising pneumonia
2020 · Robert Perry, Dimitrios Christidis, et al. · JRSM Open · 4
PDF
Navigating the benefits and burdens of life-saving treatment in severely decompensated cirrhosis: an illustrative, multisourced narrative
2017 · Philip Berry, Kuldeep Cheent, et al. · BMJ Case Reports · 3
P379 Group and individualised feedback to operators improves the adequacy of liver biopsy
2021 · Megan Toksvig-Stewart, Robert Perry, et al. · Gut · 2
PDF
Treatment with elafibranor to normalize alkaline phosphatase in patients with primary biliary cholangitis and incomplete response to ursodeoxycholic acid: Results from the phase III randomized controlled ELSPIRE trial
2026 · Kris V. Kowdley, Eric Lawitz, et al. · Hepatology · 1
Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581]
2021 · Heather J. Cordell, James J. Fryett, et al. · Journal of Hepatology · 1
PDF
P55 Looking for a needle in a Haystack: outcomes of the surrey hepatitis C/PHE lookback exercise. Re-engaging patients in a low prevalence ODN
2020 · Osob Mohamed, Elizabeth Harrod, et al. · Gut · 1
PDF
PWE-117 The role of repeat liver biopsies in autoimmune hepatitis: clinical practice and outcomes
2015 · S Mathew, R Narang, et al. · Gut · 1
Reduced venesection requirement as a clue to occult colorectal cancer in hereditary haemochromatosis
2026 · Roisin Burrows-O’Donoghue, Yee Tin Lit, et al. · BMJ Case Reports
P118 aMAP risk stratification as a tool to rationalise hepatocellular carcinoma surveillance in the UK: a single district general hospital experience
2026 · Ali Hakizimana, Grace Bambury, et al. · Gut
PDF
P46 Real-world biochemical response to elafibranor in PBC across second-line treatment subgroups: a United Kingdom regional centre experience
2026 · Rachael Kamiri-Ngugi, Charlie Piercy, et al. · Gut
PDF
P45 Early real-world evaluation of elafibranor in primary biliary cholangitis: a UK PBC regional network perspective
2025 · Rachael Kamiri-ngugi, Chris Cussen, et al. · Gut
O2 Implementing a nurse-led early discharge clinic for patients with decompensated chronic liver disease to reduce readmission rates and length of hospital stay
2025 · Liliana Goncalves King, Iona Coltart, et al. · Gut
P50 Real-world delays in primary biliary cholangitis diagnosis: a 17-year retrospective audit of time from ALP elevation to diagnosis
2025 · Parmis Vafapour, Molly Butler, et al. · Gut
Works count: 38
Citation count: 1,132
H-index: 10
I10-index: 10
Year
Topic
Type